All five candidates, including fixed-dose combinations, rely on the company's POTENT technology, which Ascletis says is built to improve absorption of oral peptides.
Recap by typeshit. Full story at RTTNews.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
BusinessWorld Online covers a Lilly weight loss drug still in clinical trials. Few details were given beyond the headline.
A short social post says drugs like Ozempic may lower heart attack and stroke risk, possibly beyond what weight loss alone explains.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
10:00
A general explainer video from the Healthy Benefits channel on how the body responds to tirzepatide when it is used for weight loss.
Loading…